Navigation Links
Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
Date:12/3/2010

DALLAS and NEW YORK, Dec. 3, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has updated its lead product website, www.MuGard.com, with its first patient MuGard experience testimonial video and additional clinician feedback.  

The video can be found under the Testimonial section of the MuGard website (www.MuGard.com), or by clicking on the following link: www.MuGard.com/testimonials/.

"We continue receiving many anecdotal feedback and testimonials from patients, doctors, and nurses," said Frank Jacobucci, VP of Sales and Marketing, Access Pharmaceuticals.  He continued, "We are gratified at the overwhelmingly positive reception MuGard is receiving in the oncology community and we plan to continue updating the site with additional testimonials that demonstrate the significant clinical benefit experienced using MuGard in both a prophylactic and treatment setting."

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps Access to Physicians
2. Consortium on Intraosseous (IO) Vascular Access Recommends IO Access for Emergent and Nonemergent Situations
3. Reportlinker Adds Global HPLC Systems & Accessories Industry
4. Access Pharmaceuticals ProLindac™ and CobaCyte™ Oncology Research Displayed at the Innovations in Cancer Prevention and Research Conference, November 17-19, 2010
5. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
6. Access Pharmaceuticals to Present at LifeTech Capital Miami Medical Investors Conference on November 12th
7. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
8. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
9. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
10. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
11. Access Pharmaceuticals Signs Agreement With Leading Biopharmaceutical Company to Develop CobOral™ Formulation of Widely-Marketed Injectable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... "Global Markets for Emerging Medical Device Technologies" report to ... ... heart valves, open procedures, general instruments, non-drug coated implantables, large ... have been in use over the last two to three ...
(Date:2/16/2017)... , Feb. 16, 2017 The Lockwood Group (Lockwood), ... Best Place to Work in Connecticut ... the third year in a row that Lockwood has been ... to earn the number-two spot in 2017. The award recognizes ... excellence. The winners were determined through a survey conducted by ...
(Date:2/16/2017)... 16, 2017  Prescription pain medications provided by "physicians ... necessary for long-term opioid use to take hold," according ... edition of The New England Journal of ... more patients in acute pain than in almost any ... FACEP, president of the American College of Emergency Physicians. ...
Breaking Medicine Technology:
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette White, ... Pet Life Radio network. The episode, which was posted this week, features a ... factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association of ...
(Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... that allow for the electronic prescribing of controlled and non-controlled substances plus the ... percent of pharmacies in the United States now accept electronic prescriptions, according to ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering ... Francis' goals for each and every seminar, session and class she offers. ... five different brainwave tools which help energize creativity, focus mental functions, enhance athletic ...
Breaking Medicine News(10 mins):